Uncategorized
Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema
OXFORD, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oxular Limited, a clinical-stage ophthalmic company developing long-lasting treatments for retinal disorders, today announces that it has begun dosing in its OXEYE Phase 2 clinical trial evaluating the company’s lead product candidate, suprachoroidal OXU-001, for the treatment of diabetic macular edema (DME). OXEYE is designed to evaluate the safety, efficacy, and durability of OXU-001 as an innovative treatment option, combining poten